We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

15 hedge funds and large institutions have $1.24M invested in Titan Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

239% more call options, than puts

Call options by funds: $624K | Put options by funds: $184K

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

36% more capital invested

Capital invested by funds: $909K → $1.24M (+$331K)

0.01% more ownership

Funds ownership: 0% → 0.01% (+0.01%)

42% less funds holding

Funds holding: 26 → 15 (-11)

91% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 11

Holders
15
Holders Change
-11
Holders Change %
-42.31%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
2
Closed
11
Calls
$624K
Puts
$184K
Net Calls
+$440K
Net Calls Change
+$436K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$178K
2
ARTA
A.R.T. Advisors
New York
+$42.7K
3
Northern Trust
Northern Trust
Illinois
+$10.7K
4
UBS Group
UBS Group
Switzerland
+$7.77K
5
Morgan Stanley
Morgan Stanley
New York
+$4.86K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$58K
2
VF
Virtu Financial
New York
-$53K
3
Citadel Advisors
Citadel Advisors
Florida
-$22.3K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$20.4K
5
WPA
Winning Points Advisors
Florida
-$10.7K

TTNP Hedge Fund Activity: Q1 2019 in Review

15 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2019, worth a combined $1.24M — up 36% from $909K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of TTNP and 1 opened new positions — a net loss of 10 holders — while 2 trimmed existing stakes and 4 added.

The largest buyer was Vanguard Group, adding an estimated $178K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $58K sold.

  • 15 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2019, down from 26 in Q4 2018.
  • Funds reported $1.24M of Titan Pharmaceuticals stock for Q1 2019, up 36% quarter-over-quarter.
  • 1 fund opened new Titan Pharmaceuticals positions in Q1 2019 and 11 closed out, a net change of -10 holders.
  • The largest Titan Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $178K added.
  • The largest Titan Pharmaceuticals seller in Q1 2019 was Renaissance Technologies, an estimated $58K sold.

Based on aggregated 13F filings for Q1 2019.